STCube

STCube R&D Expenses

The Research & Development Expenses of STCube (052020.KQ) as of Oct 18, 2026 is 11.15 B KRW. In the previous year, Research & Development Expenses was 13.15 B KRW — a change of -15.24% (lower).

R&D Expenses

11.15 BKRW

YoY

-15.24%

Last updated:

Research & Development Expenses of STCube is 2025 11.15 B KRW. Research & Development Expenses of STCube was 2024 13.15 B KRW. It decreases by -15.24% lower compared to the previous year.

The STCube R&D Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D Expenses
Date
R&D Expenses
Jan 1, 2018
4.31 B KRW
Jan 1, 2019
4.09 B KRW
Jan 1, 2020
5.56 B KRW
Jan 1, 2021
11.25 B KRW
Jan 1, 2022
10.16 B KRW
Jan 1, 2023
15.94 B KRW
Jan 1, 2024
13.15 B KRW
Jan 1, 2025
11.15 B KRW
The STCube R&D Expenses history
YEARR&D ExpensesYoY
11.15 BKRW-15.24%
13.15 BKRW-17.48%
15.94 BKRW+56.83%
10.16 BKRW-9.61%
11.25 BKRW+102.25%
5.56 BKRW+35.90%
4.09 BKRW-5.15%
4.31 BKRW+17.87%
3.66 BKRW+1,220.46%
277.13 MKRW-86.71%
2.08 BKRW+14.24%
1.82 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

STCube Stock analysis

What does STCube do? STCube Inc is a company based in Seoul, South Korea, operating within the Information Technology sector and Electrical Equipment industry. The company went public on July 5, 2001, with its ticker symbol 052020.KQ and ISIN KR7052020005. STCube Inc provides information technology services, focusing on the distribution of closed-circuit television (CCTV) lenses and related components. The company also engages in the development and licensing of immunomodulatory anticancer drug therapeutic candidates. STCube Inc's business is structured through two segments: the Information Technology segment, which handles the distribution of CCTV lenses and components, and the Biotechnology segment, which is involved in the development and licensing of drug candidates for cancer treatment. The company's official website is http://www.stcube.com/. STCube Inc is headquartered in Seoul, South Korea, and operates as a publicly traded entity on the Korean stock market. The company's activities span both technology and biotechnology fields, reflecting a diversified approach to product and service offerings in these sectors. The company's operations are centered around its headquarters in Seoul, with no additional locations specified in the provided information. STCube Inc's business model integrates IT services with biotechnology research and development, targeting both commercial and medical markets. STCube is one of the most popular companies on Eulerpool.

Frequently Asked Questions about STCube stock

Research & Development Expenses of STCube is 11.15 B KRW in 2025.

Research & Development Expenses of STCube changed from 13.15 B KRW to 11.15 B KRW, representing a -15.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Research & Development Expenses STCube since 2006 – with annual values, charts, and detailed analysis.

R&D expenses represent the costs incurred in researching and developing new products, services, or processes. High R&D spending can signal innovation and future growth potential.

Research & Development Expenses's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Research & Development Expenses's STCube historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — STCube

All Key Metrics — STCube